Radiopharmaceutical Dealmaking Continues With Telix’s $1.65B ITM Acquisition

Telix Pharmaceuticals is acquiring Isotope Technologies Munich, or ITM, in a $1.65 billion stock deal that will create a radiopharmaceuticals company with greater global scale. ITM’s lead pipeline asset is in late-stage development for a type of gastrointestinal cancer, where it could compete against Novartis and Curium Pharma products. The post Radiopharmaceutical Dealmaking Continues With…

Read More

Electra’s Upsized IPO Lands $350M for New Class of Precision Immunology Drugs

Electra Therapeutics’ IPO cash will support a potential first-in-class drug whose lead indication is a rare hyperinflammatory disorder with no FDA-approved treatments. Meanwhile, clinical-stage biotechs Marea Therapeutics and Sensorion revealed their respective plans to enter the U.S. public markets. The post Electra’s Upsized IPO Lands $350M for New Class of Precision Immunology Drugs appeared first…

Read More